CHIPSCREEN BIOSCIENCES has started phase III clinical study of Chiglitazar in 2014, which has lasted nearly two years so far. Up till now, the CMAS test of the new drug was completed on June 30, 2016 and the CMAP test was completed on September 30, 2016. The two tests included 1278 subjects in the group.

About Chiglitazar

With the deepening of the research on type 2 diabetes, reducing blood sugar is not the ultimate goal in the treatment of diabetes. More importantly, reducing or treating various complications of diabetes such as coronary heart disease, heart failure, stroke and other vascular diseases and microvascular diseases such as kidney disease and retinal disease in parallel can reduce mortality and improve the quality of life of patients. Therefore, the research and development of new diabetes treatment drugs with long-term hypoglycemic effect, potential benefits of cardiovascular safety and long-term medication safety is still an important goal of new drug research and development in this field. Since the glucose and lipid metabolism in the body is a complex and interactive physiological process, it is a typical case that the intensive lipid lowering of statins will increase the incidence of new diabetes mellitus in clinical trials. Therefore, the requirement for research and development of new drug should be to have a balanced effect on glucose and lipid metabolism. It is based on this concept to develop Chiglitazar, the new generation of insulin sensitizer drugs.

Chiglitazar is a new type of insulin sensitizer candidate drug independently designed, synthesized, screened and developed by CHIPSCREEN BIOSCIENCES. It is the first original chemical class 1.1 new drug in our country to treat type 2 diabetes and a major national drug discovery project, which is currently carrying out a phase III clinical study of registration and is expected to be marketed in 2018. In the treatment of type 2 diabetes, Chiglitazar not only can control blood sugar, but also can treat the disorder of lipid metabolism and abnormal blood pressure accompanied by patients, which may be beneficial to the prevention and control of cardiovascular complications, and is expected to become a new and more comprehensive drug treatment method for type 2 diabetes.